These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 17192505)

  • 1. The role of SN-38 exposure, UGT1A1*28 polymorphism, and baseline bilirubin level in predicting severe irinotecan toxicity.
    Ramchandani RP; Wang Y; Booth BP; Ibrahim A; Johnson JR; Rahman A; Mehta M; Innocenti F; Ratain MJ; Gobburu JV
    J Clin Pharmacol; 2007 Jan; 47(1):78-86. PubMed ID: 17192505
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan.
    Innocenti F; Undevia SD; Iyer L; Chen PX; Das S; Kocherginsky M; Karrison T; Janisch L; Ramírez J; Rudin CM; Vokes EE; Ratain MJ
    J Clin Oncol; 2004 Apr; 22(8):1382-8. PubMed ID: 15007088
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism.
    Iyer L; Hall D; Das S; Mortell MA; Ramírez J; Kim S; Di Rienzo A; Ratain MJ
    Clin Pharmacol Ther; 1999 May; 65(5):576-82. PubMed ID: 10340924
    [TBL] [Abstract][Full Text] [Related]  

  • 4. UGT1A1 promoter genotype correlates with SN-38 pharmacokinetics, but not severe toxicity in patients receiving low-dose irinotecan.
    Stewart CF; Panetta JC; O'Shaughnessy MA; Throm SL; Fraga CH; Owens T; Liu T; Billups C; Rodriguez-Galindo C; Gajjar A; Furman WL; McGregor LM
    J Clin Oncol; 2007 Jun; 25(18):2594-600. PubMed ID: 17577039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Relationship between UGT1A1 gene polymorphisms and irinotecan-induced severe adverse events].
    Wang XF; Ma C; Gong FF; Yi SY; Xing GC; Wang KJ; Yang Q; Cao W
    Zhonghua Zhong Liu Za Zhi; 2018 Aug; 40(8):594-599. PubMed ID: 30139029
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinical observations on associations between the UGT1A1 genotype and severe toxicity of irinotecan.
    Lu YY; Huang XE; Wu XY; Cao J; Liu J; Wang L; Xiang J
    Asian Pac J Cancer Prev; 2014; 15(7):3335-41. PubMed ID: 24815493
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polymorphisms of UDP-glucuronosyltransferase and pharmacokinetics of irinotecan.
    Ando Y; Ueoka H; Sugiyama T; Ichiki M; Shimokata K; Hasegawa Y
    Ther Drug Monit; 2002 Feb; 24(1):111-6. PubMed ID: 11805731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacogenetic impact of polymorphisms in the coding region of the UGT1A1 gene on SN-38 glucuronidation in Japanese patients with cancer.
    Araki K; Fujita K; Ando Y; Nagashima F; Yamamoto W; Endo H; Miya T; Kodama K; Narabayashi M; Sasaki Y
    Cancer Sci; 2006 Nov; 97(11):1255-9. PubMed ID: 16965601
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics.
    Innocenti F; Kroetz DL; Schuetz E; Dolan ME; Ramírez J; Relling M; Chen P; Das S; Rosner GL; Ratain MJ
    J Clin Oncol; 2009 Jun; 27(16):2604-14. PubMed ID: 19349540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. UGT1A1*28 polymorphism predicts irinotecan-induced severe toxicities without affecting treatment outcome and survival in patients with metastatic colorectal carcinoma.
    Liu CY; Chen PM; Chiou TJ; Liu JH; Lin JK; Lin TC; Chen WS; Jiang JK; Wang HS; Wang WS
    Cancer; 2008 May; 112(9):1932-40. PubMed ID: 18300238
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Severe irinotecan-induced toxicity in a patient with UGT1A1 28 and UGT1A1 6 polymorphisms.
    Xu JM; Wang Y; Ge FJ; Lin L; Liu ZY; Sharma MR
    World J Gastroenterol; 2013 Jun; 19(24):3899-903. PubMed ID: 23840132
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genotype-directed, dose-finding study of irinotecan in cancer patients with UGT1A1*28 and/or UGT1A1*6 polymorphisms.
    Satoh T; Ura T; Yamada Y; Yamazaki K; Tsujinaka T; Munakata M; Nishina T; Okamura S; Esaki T; Sasaki Y; Koizumi W; Kakeji Y; Ishizuka N; Hyodo I; Sakata Y
    Cancer Sci; 2011 Oct; 102(10):1868-73. PubMed ID: 21740478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Examination of UGT1A1 polymorphisms and irinotecan-induced neutropenia in patients with Colorectal cancer].
    Teruya T; Nakachi A; Shimabukuro N; Toritsuka D; Azuma Y; Hanashiro K; Nishiki T; Ota M; Shimabuku M; Shiroma H
    Gan To Kagaku Ryoho; 2015 May; 42(5):585-9. PubMed ID: 25981652
    [TBL] [Abstract][Full Text] [Related]  

  • 14. UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer.
    Marcuello E; Altés A; Menoyo A; Del Rio E; Gómez-Pardo M; Baiget M
    Br J Cancer; 2004 Aug; 91(4):678-82. PubMed ID: 15280927
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insights, challenges, and future directions in irinogenetics.
    Kim TW; Innocenti F
    Ther Drug Monit; 2007 Jun; 29(3):265-70. PubMed ID: 17529881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis.
    Ando Y; Saka H; Ando M; Sawa T; Muro K; Ueoka H; Yokoyama A; Saitoh S; Shimokata K; Hasegawa Y
    Cancer Res; 2000 Dec; 60(24):6921-6. PubMed ID: 11156391
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Severe irinotecan-induced toxicities in a patient with uridine diphosphate glucuronosyltransferase 1A1 polymorphism.
    Mehra R; Murren J; Chung G; Smith B; Psyrri A
    Clin Colorectal Cancer; 2005 May; 5(1):61-4. PubMed ID: 15929808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. UGT1A1 Gene Polymorphism Predicts Irinotecan-Induced Severe Neutropenia and Diarrhea in Chinese Cancer Patients.
    Peng H; Duan Z; Pan D; Wen J; Wei X
    Clin Lab; 2017 Sep; 63(9):1339-1346. PubMed ID: 28879724
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Usefulness of one-point plasma SN-38G/SN-38 concentration ratios as a substitute for UGT1A1 genetic information after irinotecan administration.
    Hirose K; Yamashita K; Takada H; Kaneda N; Fukami K; Maruo E; Kitamura M; Hasegawa J; Maeda Y
    Int J Clin Oncol; 2014 Apr; 19(2):397-402. PubMed ID: 23605141
    [TBL] [Abstract][Full Text] [Related]  

  • 20. UGT1A1 genotyping: a predictor of irinotecan-associated side effects and drug efficacy?
    Schulz C; Boeck S; Heinemann V; Stemmler HJ
    Anticancer Drugs; 2009 Nov; 20(10):867-79. PubMed ID: 19770637
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.